Advanced

Acute onset of ovarian dysfunction in young females after start of cancer treatment.

Mörse, Helena LU ; Elfving, Maria LU ; Lindgren, Anna LU ; Wölner-Hanssen, Pål LU ; Andersen, Claus Yding and Øra, Ingrid LU (2013) In Pediatric Blood & Cancer2004-01-01+01:00 60(4). p.676-681
Abstract
BACKGROUND:

Female childhood cancer survivors are at risk of ovarian failure and premature ovarian insufficiency. We hereby present an interim analysis of a prospective observational study of ovarian function during cancer treatment of young females in relation to clinical factors.



PROCEDURE: Thirty-four consecutive female cancer patients aged 0-18 year were included after informed consent. Serum/Plasma levels of anti-Müllerian hormone (AMH), inhibin B, FSH, LH, and oestradiol (E2) were measured at diagnosis and every 3-4 months during and after treatment.



RESULTS: All patients had detectable AMH levels at diagnosis. Eleven patients had reached menarche (mean age 14½ years) and the... (More)
BACKGROUND:

Female childhood cancer survivors are at risk of ovarian failure and premature ovarian insufficiency. We hereby present an interim analysis of a prospective observational study of ovarian function during cancer treatment of young females in relation to clinical factors.



PROCEDURE: Thirty-four consecutive female cancer patients aged 0-18 year were included after informed consent. Serum/Plasma levels of anti-Müllerian hormone (AMH), inhibin B, FSH, LH, and oestradiol (E2) were measured at diagnosis and every 3-4 months during and after treatment.



RESULTS: All patients had detectable AMH levels at diagnosis. Eleven patients had reached menarche (mean age 14½ years) and the remaining patients had a mean age of 6½ years. They all showed a rapid decline in AMH after 3 months of treatment, regardless of AMH at diagnosis, age, menarche, or treatment given. Those given radiotherapy below the diaphragm and/or stem cell transplantation (SCT) (n = 9) had no ovarian recovery during or 1½-year after treatment. However, recovery was observed in those given standard treatment for acute lymphatic leukemia (n = 7) already during maintenance chemotherapy. For the remaining patients, longer follow-up is required for analysis of ovarian recovery after treatment.



CONCLUSIONS: Rapid ovarian dysfunction is observed in all females after initiation of cancer treatment as measured by AMH and inhibin B. Our data regarding those who require abdominal radiotherapy and/or SCT confirms the recommendations in the Nordic countries where these patients are eligible for cryopreservation of ovarian cortical tissue before start of cancer treatment. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Pediatric Blood & Cancer2004-01-01+01:00
volume
60
issue
4
pages
676 - 681
publisher
John Wiley and Sons Inc.
external identifiers
  • wos:000316291400027
  • pmid:23015461
  • scopus:84873710424
ISSN
1545-5017
DOI
10.1002/pbc.24327
language
English
LU publication?
yes
id
2cf97449-3b29-4514-9e48-33b716150a03 (old id 3123610)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23015461?dopt=Abstract
date added to LUP
2012-10-03 21:04:40
date last changed
2019-04-02 01:13:40
@article{2cf97449-3b29-4514-9e48-33b716150a03,
  abstract     = {BACKGROUND: <br/><br>
Female childhood cancer survivors are at risk of ovarian failure and premature ovarian insufficiency. We hereby present an interim analysis of a prospective observational study of ovarian function during cancer treatment of young females in relation to clinical factors. <br/><br>
<br/><br>
PROCEDURE: Thirty-four consecutive female cancer patients aged 0-18 year were included after informed consent. Serum/Plasma levels of anti-Müllerian hormone (AMH), inhibin B, FSH, LH, and oestradiol (E2) were measured at diagnosis and every 3-4 months during and after treatment. <br/><br>
<br/><br>
RESULTS: All patients had detectable AMH levels at diagnosis. Eleven patients had reached menarche (mean age 14½ years) and the remaining patients had a mean age of 6½ years. They all showed a rapid decline in AMH after 3 months of treatment, regardless of AMH at diagnosis, age, menarche, or treatment given. Those given radiotherapy below the diaphragm and/or stem cell transplantation (SCT) (n = 9) had no ovarian recovery during or 1½-year after treatment. However, recovery was observed in those given standard treatment for acute lymphatic leukemia (n = 7) already during maintenance chemotherapy. For the remaining patients, longer follow-up is required for analysis of ovarian recovery after treatment. <br/><br>
<br/><br>
CONCLUSIONS: Rapid ovarian dysfunction is observed in all females after initiation of cancer treatment as measured by AMH and inhibin B. Our data regarding those who require abdominal radiotherapy and/or SCT confirms the recommendations in the Nordic countries where these patients are eligible for cryopreservation of ovarian cortical tissue before start of cancer treatment. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc.},
  author       = {Mörse, Helena and Elfving, Maria and Lindgren, Anna and Wölner-Hanssen, Pål and Andersen, Claus Yding and Øra, Ingrid},
  issn         = {1545-5017},
  language     = {eng},
  number       = {4},
  pages        = {676--681},
  publisher    = {John Wiley and Sons Inc.},
  series       = {Pediatric Blood & Cancer2004-01-01+01:00},
  title        = {Acute onset of ovarian dysfunction in young females after start of cancer treatment.},
  url          = {http://dx.doi.org/10.1002/pbc.24327},
  volume       = {60},
  year         = {2013},
}